In this exclusive interview, CEO of NewAmsterdam Pharma, Michael Davidson, offers insight into the low-density lipoprotein (LDL) cholesterol lowering therapeutic landscape and shares promising data from the company’s lead candidate, a cholesterol ester transfer protein (CETP) inhibitor.
List view / Grid view
A Phase II trial for the small interfering RNA (siRNA) therapeutic lepodisiran is currently underway, assessing its ability to reduce lipoprotein(a) levels.
The EMA’s safety board verifies that amfepramone-containing products for obesity should not be sold, due to higher-associated health risks.
This article highlights the 10 most popular news stories published by European Pharmaceutical Review in 2019.
As the demand for safety-syringes increases, the market for pre-filled safety-engineered devices will increase. This article outlines the main drivers behind this growth.
A combination therapy using the blood thinner cilostazol, along with either aspirin or clopidogrel, was shown to decrease the risk of stroke recurrence...
Mayo study uses artificial intelligence to create inexpensive, widely available early detector of heart disease...
Raman spectroscopy can help to detect post-traumatic stress disorder syndrome by revealing the levels of stress hormone in human hair.
Percutaneous coronary intervention (PCI), along with prescribed medication, is better than medication alone as initial treatment for people with the most common form of heart disease.
Nicotinamide riboside was shown to mimic caloric restriction, boosting arterial health...
Researchers have found that incorporating imaging technologies more precisely can predict heart attack risk...
A team of scientists in Italy has developed a 3d model that uniquely presents an holistic demonstration of how the left-hand chambers of the heart interact with blood flow and its component parts. The ultimate aim is better prevention and treatment of cardiac conditions.